{"denoms":[{"counts":[{"groupId":"BG000","value":"228"},{"groupId":"BG001","value":"224"},{"groupId":"BG002","value":"452"}],"units":"Participants"}],"groups":[{"description":"Eribulin mesylate at a dose of 1.4 mg/m\\^2 was administered IV as a bolus infusion over 2-5 minutes on Days 1 and 8 of every 21-day treatment cycle.","id":"BG000","title":"Arm A: Eribulin Mesylate"},{"description":"Dacarbazine at a dose of 850 mg/m\\^2, 1000 mg/m\\^2, or 1200 mg/m\\^2 (as selected by the Principal Investigator \\[PI\\] or designee prior to randomization according to the participant's clinical status) was administered as an IV infusion over 15-30 minutes (or up to 60 minutes as per institutional guidelines) on Day 1 of every 21-day treatment cycle.","id":"BG001","title":"Arm B: Dacarbazine"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.01","value":"55.6"},{"groupId":"BG001","spread":"10.35","value":"55.7"},{"groupId":"BG002","spread":"10.68","value":"55.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"GEOMETRIC_MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"161"},{"groupId":"BG001","value":"142"},{"groupId":"BG002","value":"303"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"82"},{"groupId":"BG002","value":"149"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Full analysis set (FAS) (Intent-to-Treat (ITT) analysis set) included all participants who were randomized."}